Welcome to the PAD 2020 Exhibitor Hub!
Your one-stop shop for all things 2020 PAD exhibitors.
For each Exhibitor Zoom Room you visit, the PAD will donate $1 to the Public Health Education Fund.
For each Exhibitor Zoom Room you visit, the PAD will donate $1 to the Public Health Education Fund.
Exhibitor Flipbook
Exhibitor Scavenger Hunt
Complete the Exhibitor Scavenger Hunt by Friday, November 20 to be entered to win a $300 Apple or Amazon Gift Certificate.
Exhibit Gallery
Abbott
www.juven.com | Facebook | Instagram About Abbott Abbott is making an everlasting impact on human health as one of the world's leading authorities in science-based nutrition nourishing every stage of life. As your lifelong nutrition partner and advocate, we invite you to our booth to sample our therapeutic nutritional powder for wound healing. Visit Juven.com to find additional product information, clinical research, delicious recipes and more. Representatives JoAnn Tack, joann.tack@abbott.com Kellie Warner Handouts Williams Clinical Summary The Use of a Specialized Nutritional Supplement for Diabetic Foot Ulcers Reduces the Use of Antibiotics |
|
Abbvie
www.abbvie.com Twitter | Facebook | Instagram |YouTube | LinkedIn. About Abbvie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Corporate Websites ABV Website ABV COVID Response ABV Medical Info Branded Websites HCP Website 1 HCP Website 2 HCP Website 3 Handouts Head to Head Data |
AMGEN
www.amgen.com About AMGEN Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. |
Dermpath Diagnostics
www.dermpathdiagnostics.com Facebook | Twitter | LinkedIn About Dermpath Diagnostics Dermpath Diagnostics is exclusively focused on providing exceptional dermatopathology services. Our commitment to dermatopathology is backed by an unrivaled team of over 75 board-certified dermatopathologists, advanced diagnostic technologies and a proficient support team dedicated to serve you, your staff and patients. Our mission is to provide accurate, clear and prompt diagnoses. Through the development of strong consultative relationships with each of our referring clinicians, together we will provide the best possible care for every patient. Representative Rick Lavelle, rlavelle@dermpathdiagnostics.com |
Genentech
website About Genentech Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Representatives Dave Papzian, papazian.david@gene.com Jeff Statsman, statsmaj@gene.com Doug Doehring, doehrind@gene.com Meeting ID: 279 529 3819
Passcode: 765323 |
Janssen
www.janssen.com About Janssen At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. |
Myriad
LinkedIn | Twitter | Facebook Click here to learn more about myPath Melanoma. Click here to learn more about Myriad Genetics Click here to learn about myRisk, the multi-gene panel genetic test that identifies patients at risk for hereditary cancer in 8 different cancer sites, including melanoma ![]() About Myriad
Myriad's myPath Melanoma test is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. For almost 30 years, Myriad Genetics has been at the forefront of precision medicine, transforming people's lives with pioneering molecular diagnostic tests. We answer people's FOUR most pressing questions about disease so they can benefit from the information and live longer, healthier lives. 1. Risk: Will I get the disease? 2. Diagnosis/Screening: Do I have the disease? 3. Prognosis: Should I treat this disease? 4. Therapy: How should I treat this disease? We are making the promise of precision medicine a reality in SIX medical specialties and for millions of people worldwide whose lives will be transformed by our products. Representative Jason Rose, jason.rose@myriad.com |
What does EXPERIENCE mean to you and for your patients?
Visit virtualboothexperience.com to learn more about the Complete Cosentyx Approach. Please click here for full Prescribing Information, including Medication Guide, for COSENTYX. © 2020 Novartis 10/20 COS-1396860 Representatives Laura Close, laura.close@novartis.com Shannon Thomas, shannon.thomas@novartis.com |
PP-CRI-USA-2698 ©2020 Pfizer Inc. All rights reserved. October 2020.
|
Pfizer
Handouts EUCRISA 5-Year-Old Case Report EUCRISA 18-Year-Old and 14-Year-Old Case Report INDICATION EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. IMPORTANT SAFETY INFORMATION Contraindications EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation. Warnings and Precautions Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur. Adverse Reactions The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging. Please see Full Prescribing Information |
Contact Us
medical.information@regeneron.com About DUPIXENT® See What’s Possible with DUPIXENT® (dupilumab). Learn more about the clinical efficacy, MOA and safety profile of DUPIXENT via the links to the product website and full prescribing information below. Handouts
DUPIXENT® MyWay Getting Started Brochure DUPIXENT® Dosing Information Privacy Policy Sanofi Privacy Policy: https://www.sanofi.us/en/legal-notice/#Privacypolicy Regeneron Privacy Policy: https://www.regeneron.com/privacy-policy DUPIXENT® is a registered trademark of Sanofi Biotechnology. ©2020 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 10/2020 DUP.20.10.0001 |
Sun Pharmaceutical Industries, Inc., - Sun Dermatology
https://www.ilumyapro.com/ About Sun Dermatology Sun Dermatology (the branded dermatology division of a wholly owned subsidiary of Sun Pharmaceutical Industries Inc.) is committed to expanding its dermatology portfolio to bring healthcare providers and patients around the world more treatment options and ongoing support for conditions like moderate-to-severe plaque psoriasis. Sun Pharmaceutical Industries Ltd., along with its subsidiaries, is ranked second in dermatology prescription volume within the U.S. per IQVIA and is the fourth largest specialty generic pharmaceutical company globally. In addition to ILUMYA, Sun Dermatology is comprised of several branded products with a focus on various dermatologic conditions. Representative Corrie Lueker, corrie.lueker@sunpharma.com You can also dial in using your phone.
United States: +1 (571) 317-3116 Access Code: 480-878-269 |
UCB
https://www.ucb.com/ About UCB At UCB, we come together to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we live. How we do business – from discovery to development to delivery – has been transformed and redesigned around the patient’s individual experience. Patients are at the heart of everything we do, inspiring us and driving our scientific discovery. By fulfilling our commitment and providing patients a meaningful experience, more impactful solutions are on the horizon. With a team of approximately 7,500 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia and sites in Raleigh and Durham, North Carolina, Boston, Massachusetts, Seattle, Washington, and Washington, D.C. |